Endogenous and xenobiotic metabolite profiling of liver extracts from SCID and chimeric humanized mice following repeated oral administration of troglitazone

References

• Chen AA, Thomas DK, Ong LL, et al. (2011). Humanized mice with ectopic artificial liver tissues. Proc Natl Acad Sci USA 108:11842--7
   PubMed Web of Science ®Google Scholar
• Cloarec O, Dumas M-E, Craig A, et al. (2005). Statistical total correlation spectroscopy: an exploratory approach for latent biomarker identification from metabolic 1H NMR data sets. Anal Chem 77:1282–9
   PubMed Web of Science ®Google Scholar
• Cloarec O, Dumas ME, Trygg J, et al. (2004). Evaluation of the orthogonal projection on latent structure model limitations caused by chemical shift variability and improved visualization of biomarker changes in 1H NMR spectroscopic metabonomic studies. Anal Chem 77:517–26
   Web of Science ®Google Scholar
• FDA Guidance on safety testing of drug metabolites. (2008). Available from: http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm079266.pdf
   Google Scholar
• Foster JR, Jacobsen M, Kenna G, et al. (2012). Differential effect of troglitazone on the human bile acid transporters, MRP2 and BSEP, in the PXB hepatic chimeric mouse. Toxicol Pathol 40:1106–16
   PubMed Web of Science ®Google Scholar
• Gorden DL, Ivanova PT, Myers DS, et al. (2011). Increased diacylglycerols characterize hepatic lipid changes in progression of human nonalcoholic fatty liver disease; comparison to a murine model. PLoS ONE 6:e22775
   Web of Science ®Google Scholar
• He K, Talaat RE, Pool WF, et al. (2004). Metabolic activation of troglitazone: identification of a reactive metabolite and mechanisms involved. Drug Metab Dispos 32:639–46
   PubMed Web of Science ®Google Scholar
• Inoue T, Nitta K, Sugihara K, et al. (2008). CYP2C9-catalyzed metabolism of S-warfarin to 7-hydroxywarfarin in vivo and in vitro in chimeric mice with humanized liver. Drug Metab Dispos 36:2429–33
   PubMed Web of Science ®Google Scholar
• Kakuni M, Morita M, Matsuo K, et al. (2012). Chimeric mice with a humanized liver as an animal model of troglitazone-induced liver injury. Toxicol Lett 214:9–18
   PubMed Web of Science ®Google Scholar
• Kamimura H, Nakada N, Suzuki K, et al. (2010). Assessment of chimeric mice with humanized liver as a tool for predicting circulating human metabolites. Drug Metab Pharmacokinet 25:223–35
   PubMed Web of Science ®Google Scholar
• Katoh M, Yokoi T. (2007). Application of chimeric mice with humanized liver for predictive ADME. Drug Metab Rev 39:145–57
   PubMed Web of Science ®Google Scholar
• Kostrubsky VE, Vore M, Kindt E, et al. (2001). The effect of troglitazone biliary excretion on metabolite distribution and cholestasis in transporter-deficient rats. Drug Metab Dispos 29:1561–6
   PubMed Web of Science ®Google Scholar
• Lee WNP, Lim S, Bassilian S, et al. (1998). Fatty acid cycling in human hepatoma cells and the effects of troglitazone. J Biol Chem 273:20929–34
   PubMed Web of Science ®Google Scholar
• Lehmann JM, Moore LB, Smith-Oliver TA, et al. (1995). An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor γ (PPARγ). J Biol Chem 270:12953–6
   PubMed Web of Science ®Google Scholar
• Loftus N, Barnes A, Ashton S, et al. (2011). Metabonomic investigation of liver profiles of nonpolar metabolites obtained from alcohol-dosed rats and mice using high mass accuracy MSn analysis. J Proteome Res 10:705–13
   PubMed Web of Science ®Google Scholar
• Loi CM, Alvey CW, Vassos AB, et al. (1999a). Steady-state pharmacokinetics and dose proportionality of troglitazone and its metabolites. J Clin Pharmacol 39:920–6
   PubMed Web of Science ®Google Scholar
• Loi C-M, Young M, Randinitis E, et al. (1999b). Clinical pharmacokinetics of troglitazone. Clin Pharmacokinet 37:91--104
   PubMed Web of Science ®Google Scholar
• Lootens L, Meuleman P, Leroux-Roels G, et al. (2011). Metabolic studies with promagnon, methylclostebol and methasterone in the uPA+/+-SCID chimeric mice. J Steroid Biochem Mol Biol 127:374–81
   PubMed Web of Science ®Google Scholar
• Nozawa T, Sugiura S, Nakajima M, et al. (2004). Involvement of organic anion transporting polypeptides in the transport of troglitazone sulfate: implications for understanding troglitazone hepatotoxicity. Drug Metab Dispos 32:291–4
   PubMed Web of Science ®Google Scholar
• Okumura H, Katoh M, Sawada T, et al. (2007). Humanization of excretory pathway in chimeric mice with humanized liver. Toxicol Sci 97:533–8
   PubMed Web of Science ®Google Scholar
• Saltiel AR, Olefsky JM. (1996). Thiazolidinediones in the treatment of insulin resistance and type II diabetes. Diabetes 45:1661–9
   PubMed Web of Science ®Google Scholar
• Schulz-Utermoehl T, Sarda S, Foster JR, et al. (2012). Evaluation of the pharmacokinetics, biotransformation and hepatic transporter effects of troglitazone in mice with humanized livers. Xenobiotica 42:503–17
   PubMed Web of Science ®Google Scholar
• Serres MD, Bowers G, Boyle G, et al. (2011). Evaluation of a chimeric (uPA+/+)/SCID mouse model with a humanized liver for prediction of human metabolism. Xenobiotica 41:464–75
   PubMed Web of Science ®Google Scholar
• Strom SC, Davila J, Grompe M. (2010). Chimeric mice with humanized liver: tools for the study of drug metabolism, excretion, and toxicity. Methods Mol Biol 640:491–509
   PubMedGoogle Scholar
• Tateno C, Yoshizane Y, Saito N, et al. (2004). Near completely humanized liver in mice shows human-type metabolic responses to drugs. Am J Pathol 165:901–12
   PubMed Web of Science ®Google Scholar
• Trygg J, Wold S. (2002). Orthogonal projections to latent structures (O-PLS). J Chemometr 16:119–28
   Web of Science ®Google Scholar
• Watkins PB, Whitcomb RW. (1998). Hepatic dysfunction associated with troglitazone. N Engl J Med 338:916–7
   PubMed Web of Science ®Google Scholar
• Watkins SM, Reifsnyder PR, Pan H-j, et al. (2002). Lipid metabolome-wide effects of the PPARγ agonist rosiglitazone. J Lipid Res 43:1809–17
   PubMed Web of Science ®Google Scholar
• Yamasaki C, Kataoka M, Kato Y, et al. (2010). In vitro evaluation of cytochrome P450 and glucuronidation activities in hepatocytes isolated from liver-humanized mice. Drug Metab Pharmacokinet 25:539–50
   PubMed Web of Science ®Google Scholar
• Yamazaki H, Shibata A, Suzuki M, et al. (1999). Oxidation of troglitazone to a quinone-type metabolite catalyzed by cytochrome P-450 2C8 and P-450 3A4 in human liver microsomes. Drug Metab Dispos 27:1260–6
   PubMed Web of Science ®Google Scholar
• Yoshizato K, Tateno C. (2009). In vivo modeling of human liver for pharmacological study using humanized mouse. Exp Opin Drug Metab Toxicol 5:1435–46
   PubMed Web of Science ®Google Scholar